Medicine and Dentistry
Hazard Ratio
80%
Genotype
80%
Patient
80%
Breast Cancer
60%
Interleukin 6
60%
Haplotype
60%
Estrogen Receptor
60%
Clinical Trial
60%
Polymerase Chain Reaction
60%
Neoplasm
40%
Disease Free Survival
40%
Promoter Region
40%
Log Rank Test
20%
Adjuvant Chemotherapy
20%
Cyclophosphamide
20%
Drug Megadose
20%
Thiotepa
20%
Phenotype
20%
Genomic DNA
20%
Immune Response
20%
Diagnosis
20%
Anthracycline
20%
Genetic Variability
20%
Growth
20%
Pyrosequencing
20%
Host
20%
Estrogen Synthesis
20%
Inpatient
20%
Observation
20%
Adjustment
20%
INIS
patients
100%
estrogens
80%
hazards
80%
cancer
60%
receptors
60%
breasts
60%
interleukins
60%
genotype
60%
data
40%
tumors
40%
diseases
40%
promoters
40%
chemotherapy
40%
genetics
20%
clinical trials
20%
growth
20%
risks
20%
phenotype
20%
production
20%
dna
20%
modeling
20%
host
20%
cooperatives
20%
doses
20%
adjustments
20%
pcr
20%
cyclophosphamide
20%
Biochemistry, Genetics and Molecular Biology
Genotyping
80%
Interleukin 6
60%
Estrogen Receptor
60%
Haplotype
60%
Promoter Region
40%
Disease Free Survival
40%
Phenotype
20%
Cyclophosphamide
20%
Immune Response
20%
Host
20%
Genetic Divergence
20%
Growth
20%
Drug Megadose
20%
Estrogen Synthesis
20%
Anthracycline
20%
Adjustment
20%
Immunology and Microbiology
Genotype
80%
Haplotype
60%
Interleukin 6
60%
Breast
60%
Promoter Region
40%
Disease Free Survival
40%
Drug Megadose
20%
Immune Response
20%
Phenotype
20%
Genetic Variability
20%
Cyclophosphamide
20%
Growth
20%
Host
20%
Estrogen Synthesis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
60%
Interleukin 6
60%
Disease Free Survival
40%
Neoplasm
40%
Chemotherapy
40%
Thiotepa
20%
Cyclophosphamide
20%
Anthracycline
20%
Genomic DNA
20%
Host
20%
Neuroscience
Estrogen Receptor
60%
Interleukin 6
60%
Promoter Region
40%
Chemotherapy
40%
Phenotype
20%
Cyclophosphamide
20%
Genomic DNA
20%
Anthracycline
20%
Pyrosequencing
20%